Author: Ravi Shankar

SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) — Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company’s corporate and financial performance.

Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.

About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓^®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.

For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com 

Expanding scientific rationale for Ampligen^® in the evolving pancreatic cancer treatment landscape, including potential complementary approaches with RAS-targeted therapies

Ampligen dosing completed in Phase 2 DURIPANC study, positioning Company for near-term clinical benefit readout that could help shape pivotal Phase 3 development

Primary Phase 2 endpoint analysis expected to begin in December 2026, with topline results anticipated in Q1 2027 and additional median overall survival and immune-response data expected mid-year 2027

OCALA, Fla., Nov. 13, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a business update on its lead Ampligen^® (rintatolimod) program in metastatic pancreatic cancer.

AIM is evaluating Ampligen’s potential role in an evolving pancreatic cancer treatment landscape, including the emergence of RAS-targeted therapies such as Revolution Medicines’ daraxonrasib. Ampligen is a selective Toll-like receptor 3 (TLR3) agonist designed to stimulate immune responses, with repeated clinical success in killer T-cell activation in the tumor microenvironment. AIM believes that its mechanism may offer opportunities for investigation alongside RAS-targeted therapies that depend on killer T-cell activation.

AIM recently outlined the scientific rationale for exploring Ampligen alongside RAS inhibition. The potential complementary role of immune modulation and RAS-targeted treatment represents an additional area of scientific interest for AIM as it evaluates future development strategies. Such combinations remain exploratory, and their safety and efficacy have not been established.

Professor Dr. C.H.J. van Eijck, Erasmus Medical Center, and AIM’s Consulting Oncologist, states, “KRAS and RAS inhibition may leave important immune barriers intact. T-cells entering the tumor can become exhausted or be suppressed by other immune cells. Combining daraxonrasib or MRTX1133 with CTLA-4 checkpoint blockade improved tumor control in pancreatic cancer models. This demonstrates that an immune treatment can improve targeted therapy in experimental settings and provides a rationale for investigating other complementary immune approaches. The proposed combination has a specific rationale: KRAS or RAS inhibition could reduce tumor burden and make surviving cancer cells more vulnerable, while Ampligen could help activate the immune response needed to control those cells. This may be particularly relevant when RAS targeted treatment recruits immune cells but does not sufficiently activate them against the cancer. Ampligen, a Toll-like receptor 3 agonist, is an ideal candidate for such investigation because it can stimulate dendritic-cell and T-cell responses. In a study of patients with advanced pancreatic cancer, Ampligen treatment was associated with changes consistent with activation of these immune cells. Higher post-treatment levels of selected dendritic-cell and CD4⁺ T-cell populations correlated with better clinical outcomes. These observations support biological activity in patients, although only a focused future clinical trial can establish that Ampligen, in combination or as a maintenance therapy, will cause better outcomes.”

AIM Chief Executive Officer Thomas K. Equels states, “I believe that Revolution Medicines’ daraxonrasib will be the first-line therapy for metastatic pancreatic cancer in the near future, and I believe Ampligen’s immune-modulating mechanism offers a compelling scientific rationale for further investigation in this setting. Importantly, as the pancreatic cancer treatment landscape evolves with the emergence of RAS-targeted therapies, we also see opportunities to explore how Ampligen could potentially complement these advances. We believe the upcoming Phase 2 DURIPANC clinical trial results will be an important step in determining how best to advance this strategy toward pivotal development. We intend to design our Phase 3 to be relevant as a maintenance therapy based upon the first-line therapies we expect in the near future – not just FOLFIRINOX.”

Third Quarter 2026 Accomplishments and Other Recent Corporate Highlights

Ampligen dosing is concluded in the Phase 2 clinical trial (“DURIPANC”) evaluating the drug in combination with AstraZeneca’s anti-PD-L1 checkpoint inhibitor Imfinzi^® (durvalumab) in patients with metastatic pancreatic cancer whose disease stabilized following first-line FOLFIRINOX chemotherapy. AIM anticipates topline clinical benefit results in Q1 2027 and survival results analyses in Q3 2027, both of which will inform next steps as AIM moves forward with the design of a pivotal Phase 3 trial in pancreatic cancer

Equels continues, “We are entering one of the most consequential periods in AIM’s pancreatic cancer development program. DURIPANC’s Ampligen dosing is complete and analysis of the clinical benefit endpoint is imminent, in Q1 2027. In mid-year 2027 we will be able to calculate median overall survival, which is viewed as the ‘gold standard’ for approval by the FDA. Our focus has been on disciplined execution and advancing Ampligen toward the clinical evidence needed to support its next stage of development. The upcoming readout represents an important milestone in AIM’s pancreatic cancer development strategy, providing an opportunity to evaluate whether Ampligen-based immunotherapy can help sustain disease control in a patient population facing limited treatment options.”

DURIPANC year-end results, together with additional median overall survival and immune-response analyses expected mid-year 2027, are anticipated to inform the design of a potential pivotal Phase 3 trial. The approaching data readout will build on earlier exploratory clinical observations from the Dutch government-approved Named Patient Program. In a subgroup of 39 Ampligen-treated patients post-chemotherapy (including either FOLFIRINOX or Gemcitabine) with a baseline neutrophil-to-lymphocyte ratio below 4.5, median overall survival was 34.8 months, measured from initiation of chemotherapy.

• Advanced Phase 2 DURIPANC toward near-term results. Completed enrollment and Ampligen dosing, with primary endpoint analysis expected to begin in December 2026 and topline clinical benefit results anticipated in Q1 2027.
• Continued preparations for potential pivotal development. Maintained focus on advancing the clinical evidence needed to inform a pivotal Phase 3 study, supported by prior engagement with Thermo Fisher Scientific’s PPD clinical research business.
• Expanded Ampligen’s strategic development opportunities. Released a new investor presentation outlining the potential scientific rationale for evaluating Ampligen alongside emerging RAS-targeted therapies in pancreatic cancer.
• Ongoing ovarian cancer analysis. We are analyzing mechanism of action data from a clinical trial in advanced recurrent ovarian cancer, with publication expected soon.
• Strengthened intellectual property protection. Announced a U.S. patent covering Ampligen in combination with pembrolizumab for cancer treatment, with protection extending to December 2039. AIM also announced patent protection for Ampligen’s use in Long COVID across Europe and the United Kingdom, expected to extend through June 2041.
• Advanced manufacturing readiness. Entered into an agreement with Sterling Pharma Solutions to manufacture additional batches of two polynucleotide precursors used in Ampligen production.
• Satisfied outstanding promissory note. In September 2026, satisfied the February 2024 promissory note with Streeterville Capital, LLC in full.

Third Quarter 2026 Financial Results

• Cash Position: Cash, cash equivalents and marketable securities totaled approximately $6.9 million as of September 30, 2026, compared with approximately $3.0 million at December 31, 2025.
• Research and Development: R&D expenses were approximately $846,000, compared with $607,000 in the prior-year period, primarily reflecting manufacturing costs associated with Ampligen precursors.
• General and Administrative: G&A expenses were approximately $2.1 million, compared with $1.8 million in the third quarter of 2025, primarily due to salary obligations and fees that had been waived in the prior-year period.
• Net Loss: Net loss was approximately $3.1 million, compared with $3.3 million in the third quarter of 2025.

Complete financial results and related disclosures are available in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: the potential of Ampligen to enhance and extend clinical benefit; the potential of combined treatment approaches to pancreatic cancer; the potential for any such effect to be durable or long-lasting; Ampligen’s potential to complement existing therapies and to overcome biological barriers that have limited treatment success in pancreatic cancer; the timing, conduct and outcome of the DURIPANC primary endpoint analyses, biomarker evaluations and overall survival follow-up; the timing and outcome of planned regulatory interactions; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen^® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen^® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ed489bd-3af0-43ff-b54d-6198403ae7d8

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Expanding scientific rationale for Ampligen^® in the evolving pancreatic cancer treatment landscape, including potential complementary approaches with RAS-targeted therapies

Ampligen dosing completed in Phase 2 DURIPANC study, positioning Company for near-term clinical benefit readout that could help shape pivotal Phase 3 development

Primary Phase 2 endpoint analysis expected to begin in December 2026, with topline results anticipated in Q1 2027 and additional median overall survival and immune-response data expected mid-year 2027

OCALA, Fla., Nov. 13, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a business update on its lead Ampligen^® (rintatolimod) program in metastatic pancreatic cancer.

AIM is evaluating Ampligen’s potential role in an evolving pancreatic cancer treatment landscape, including the emergence of RAS-targeted therapies such as Revolution Medicines’ daraxonrasib. Ampligen is a selective Toll-like receptor 3 (TLR3) agonist designed to stimulate immune responses, with repeated clinical success in killer T-cell activation in the tumor microenvironment. AIM believes that its mechanism may offer opportunities for investigation alongside RAS-targeted therapies that depend on killer T-cell activation.

AIM recently outlined the scientific rationale for exploring Ampligen alongside RAS inhibition. The potential complementary role of immune modulation and RAS-targeted treatment represents an additional area of scientific interest for AIM as it evaluates future development strategies. Such combinations remain exploratory, and their safety and efficacy have not been established.

Professor Dr. C.H.J. van Eijck, Erasmus Medical Center, and AIM’s Consulting Oncologist, states, “KRAS and RAS inhibition may leave important immune barriers intact. T-cells entering the tumor can become exhausted or be suppressed by other immune cells. Combining daraxonrasib or MRTX1133 with CTLA-4 checkpoint blockade improved tumor control in pancreatic cancer models. This demonstrates that an immune treatment can improve targeted therapy in experimental settings and provides a rationale for investigating other complementary immune approaches. The proposed combination has a specific rationale: KRAS or RAS inhibition could reduce tumor burden and make surviving cancer cells more vulnerable, while Ampligen could help activate the immune response needed to control those cells. This may be particularly relevant when RAS targeted treatment recruits immune cells but does not sufficiently activate them against the cancer. Ampligen, a Toll-like receptor 3 agonist, is an ideal candidate for such investigation because it can stimulate dendritic-cell and T-cell responses. In a study of patients with advanced pancreatic cancer, Ampligen treatment was associated with changes consistent with activation of these immune cells. Higher post-treatment levels of selected dendritic-cell and CD4⁺ T-cell populations correlated with better clinical outcomes. These observations support biological activity in patients, although only a focused future clinical trial can establish that Ampligen, in combination or as a maintenance therapy, will cause better outcomes.”

AIM Chief Executive Officer Thomas K. Equels states, “I believe that Revolution Medicines’ daraxonrasib will be the first-line therapy for metastatic pancreatic cancer in the near future, and I believe Ampligen’s immune-modulating mechanism offers a compelling scientific rationale for further investigation in this setting. Importantly, as the pancreatic cancer treatment landscape evolves with the emergence of RAS-targeted therapies, we also see opportunities to explore how Ampligen could potentially complement these advances. We believe the upcoming Phase 2 DURIPANC clinical trial results will be an important step in determining how best to advance this strategy toward pivotal development. We intend to design our Phase 3 to be relevant as a maintenance therapy based upon the first-line therapies we expect in the near future – not just FOLFIRINOX.”

Third Quarter 2026 Accomplishments and Other Recent Corporate Highlights

Ampligen dosing is concluded in the Phase 2 clinical trial (“DURIPANC”) evaluating the drug in combination with AstraZeneca’s anti-PD-L1 checkpoint inhibitor Imfinzi^® (durvalumab) in patients with metastatic pancreatic cancer whose disease stabilized following first-line FOLFIRINOX chemotherapy. AIM anticipates topline clinical benefit results in Q1 2027 and survival results analyses in Q3 2027, both of which will inform next steps as AIM moves forward with the design of a pivotal Phase 3 trial in pancreatic cancer

Equels continues, “We are entering one of the most consequential periods in AIM’s pancreatic cancer development program. DURIPANC’s Ampligen dosing is complete and analysis of the clinical benefit endpoint is imminent, in Q1 2027. In mid-year 2027 we will be able to calculate median overall survival, which is viewed as the ‘gold standard’ for approval by the FDA. Our focus has been on disciplined execution and advancing Ampligen toward the clinical evidence needed to support its next stage of development. The upcoming readout represents an important milestone in AIM’s pancreatic cancer development strategy, providing an opportunity to evaluate whether Ampligen-based immunotherapy can help sustain disease control in a patient population facing limited treatment options.”

DURIPANC year-end results, together with additional median overall survival and immune-response analyses expected mid-year 2027, are anticipated to inform the design of a potential pivotal Phase 3 trial. The approaching data readout will build on earlier exploratory clinical observations from the Dutch government-approved Named Patient Program. In a subgroup of 39 Ampligen-treated patients post-chemotherapy (including either FOLFIRINOX or Gemcitabine) with a baseline neutrophil-to-lymphocyte ratio below 4.5, median overall survival was 34.8 months, measured from initiation of chemotherapy.

• Advanced Phase 2 DURIPANC toward near-term results. Completed enrollment and Ampligen dosing, with primary endpoint analysis expected to begin in December 2026 and topline clinical benefit results anticipated in Q1 2027.
• Continued preparations for potential pivotal development. Maintained focus on advancing the clinical evidence needed to inform a pivotal Phase 3 study, supported by prior engagement with Thermo Fisher Scientific’s PPD clinical research business.
• Expanded Ampligen’s strategic development opportunities. Released a new investor presentation outlining the potential scientific rationale for evaluating Ampligen alongside emerging RAS-targeted therapies in pancreatic cancer.
• Ongoing ovarian cancer analysis. We are analyzing mechanism of action data from a clinical trial in advanced recurrent ovarian cancer, with publication expected soon.
• Strengthened intellectual property protection. Announced a U.S. patent covering Ampligen in combination with pembrolizumab for cancer treatment, with protection extending to December 2039. AIM also announced patent protection for Ampligen’s use in Long COVID across Europe and the United Kingdom, expected to extend through June 2041.
• Advanced manufacturing readiness. Entered into an agreement with Sterling Pharma Solutions to manufacture additional batches of two polynucleotide precursors used in Ampligen production.
• Satisfied outstanding promissory note. In September 2026, satisfied the February 2024 promissory note with Streeterville Capital, LLC in full.

Third Quarter 2026 Financial Results

• Cash Position: Cash, cash equivalents and marketable securities totaled approximately $6.9 million as of September 30, 2026, compared with approximately $3.0 million at December 31, 2025.
• Research and Development: R&D expenses were approximately $846,000, compared with $607,000 in the prior-year period, primarily reflecting manufacturing costs associated with Ampligen precursors.
• General and Administrative: G&A expenses were approximately $2.1 million, compared with $1.8 million in the third quarter of 2025, primarily due to salary obligations and fees that had been waived in the prior-year period.
• Net Loss: Net loss was approximately $3.1 million, compared with $3.3 million in the third quarter of 2025.

Complete financial results and related disclosures are available in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: the potential of Ampligen to enhance and extend clinical benefit; the potential of combined treatment approaches to pancreatic cancer; the potential for any such effect to be durable or long-lasting; Ampligen’s potential to complement existing therapies and to overcome biological barriers that have limited treatment success in pancreatic cancer; the timing, conduct and outcome of the DURIPANC primary endpoint analyses, biomarker evaluations and overall survival follow-up; the timing and outcome of planned regulatory interactions; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen^® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen^® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ed489bd-3af0-43ff-b54d-6198403ae7d8

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Lakewood, NJ, Nov. 13, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: XGPU) (“Reliance” or the “Company”) announced today that it will host a conference call on Monday, November 16, 2026, at 4:30 PM Eastern Time to discuss financial results for the third quarter 2026 and provide a business update. The Company expects to issue its third quarter 2026 earnings release prior to the call, and the release will be available on the investor relations section of the Company’s website at https://www.relianceglobalgroup.com.

The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 358097. A webcast of the call may be accessed at https://www.webcaster5.com/Webcast/Page/2381/54776 or on the investor relations section of the Company’s website, https://relianceglobalgroup.com/events-and-presentations/.

A webcast replay will be available on the investor relations section of the Company’s website at https://relianceglobalgroup.com/events-and-presentations/ through November 16, 2027. A telephone replay of the call will be available approximately one hour following the call, through November 30, 2026, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 54776.

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (Nasdaq: XGPU) operates insurance and technology businesses and pursues opportunities to build and scale AI-related platforms. Through the acquisition of Oblivus, the Company has entered the GPU cloud and AI infrastructure market, which it plans to scale under the GPU Exchange brand. Additional information is available at https://www.relianceglobalgroup.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You can identify these statements by terminology such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “potential,” and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding the timing of the Company’s third quarter 2026 earnings release and conference call; the Company’s plans to scale its GPU cloud and AI infrastructure business under the GPU Exchange brand; and the Company’s pursuit of opportunities to build and scale AI-related platforms.

These forward-looking statements are based on current expectations and assumptions that involve risks and uncertainties, including, among others, assumptions that the Company will be able to integrate and scale the acquired business; that the Company will be able to access capital on acceptable terms to fund its growth plans; and that market, economic and regulatory conditions will remain sufficiently favorable. There can be no assurance that these assumptions will prove accurate, and actual results could differ materially from those expressed or implied by these forward-looking statements.

Risks and uncertainties that could cause actual results to differ materially include, without limitation, delays in the completion of the Company’s quarterly financial closing and review procedures; the risk that the acquired business does not perform as anticipated; the Company’s limited operating history in the GPU cloud business; the Company’s ability to integrate and scale the acquired business; the Company’s ability to access additional capital on acceptable terms, or at all; GPU availability, pricing and technological obsolescence; customer demand, utilization and competition; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market; and general business, economic and market conditions; as well as the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended, the Company’s Quarterly Reports on Form 10-Q, and the Company’s other filings with the Securities and Exchange Commission.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: XGPU@crescendo-ir.com

Lakewood, NJ, Nov. 13, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: XGPU) (“Reliance” or the “Company”) announced today that it will host a conference call on Monday, November 16, 2026, at 4:30 PM Eastern Time to discuss financial results for the third quarter 2026 and provide a business update. The Company expects to issue its third quarter 2026 earnings release prior to the call, and the release will be available on the investor relations section of the Company’s website at https://www.relianceglobalgroup.com.

The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 358097. A webcast of the call may be accessed at https://www.webcaster5.com/Webcast/Page/2381/54776 or on the investor relations section of the Company’s website, https://relianceglobalgroup.com/events-and-presentations/.

A webcast replay will be available on the investor relations section of the Company’s website at https://relianceglobalgroup.com/events-and-presentations/ through November 16, 2027. A telephone replay of the call will be available approximately one hour following the call, through November 30, 2026, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 54776.

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (Nasdaq: XGPU) operates insurance and technology businesses and pursues opportunities to build and scale AI-related platforms. Through the acquisition of Oblivus, the Company has entered the GPU cloud and AI infrastructure market, which it plans to scale under the GPU Exchange brand. Additional information is available at https://www.relianceglobalgroup.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You can identify these statements by terminology such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “potential,” and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding the timing of the Company’s third quarter 2026 earnings release and conference call; the Company’s plans to scale its GPU cloud and AI infrastructure business under the GPU Exchange brand; and the Company’s pursuit of opportunities to build and scale AI-related platforms.

These forward-looking statements are based on current expectations and assumptions that involve risks and uncertainties, including, among others, assumptions that the Company will be able to integrate and scale the acquired business; that the Company will be able to access capital on acceptable terms to fund its growth plans; and that market, economic and regulatory conditions will remain sufficiently favorable. There can be no assurance that these assumptions will prove accurate, and actual results could differ materially from those expressed or implied by these forward-looking statements.

Risks and uncertainties that could cause actual results to differ materially include, without limitation, delays in the completion of the Company’s quarterly financial closing and review procedures; the risk that the acquired business does not perform as anticipated; the Company’s limited operating history in the GPU cloud business; the Company’s ability to integrate and scale the acquired business; the Company’s ability to access additional capital on acceptable terms, or at all; GPU availability, pricing and technological obsolescence; customer demand, utilization and competition; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market; and general business, economic and market conditions; as well as the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended, the Company’s Quarterly Reports on Form 10-Q, and the Company’s other filings with the Securities and Exchange Commission.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: XGPU@crescendo-ir.com

Promotes Dr. Vishwa Srivastava to President and Appoints Gary Lo as Chief Financial Officer

FORT LAUDERDALE, Fla., Nov. 13, 2026 (GLOBE NEWSWIRE) — via IBN —  SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment of Gary Lo as Chief Financial Officer. Dr. Vishwa Srivastava previously served as the Company’s Chief Executive Officer – Asia Pacific. Both executives are based in the United States.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “At this critical juncture in SS Innovations’ growth journey, we are excited to announce the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment of Gary Lo as Chief Financial Officer. Vishwa has been instrumental in the development and growth of our Asia Pacific region, and we are confident in his ability to successfully build our US business and lead our global operations during the next phase of expansion.”

Dr. Vishwa Srivastava said, “We have established a leading position in our immense home market of India, and I look forward to working closely with the team to build the required infrastructure and operations to further increase the presence of our advanced, cost-effective SSi Mantra surgical robotic system in the United States and globally in preparation for expansion. On that note, we have been responding to all queries raised by the U.S. Food and Drug Administration during its review of our 510(k) premarket notification for the SSi Mantra and we are simultaneously continuing along the pathway toward CE marking certification in the European Union.  Additionally, we have been working at our R&D facility in India finalizing a pipeline of future disruptive healthcare technologies that we plan to roll out in the coming months.”

Dr. Sudhir Srivastava continued, “Gary brings to SS Innovations more than three decades of financial leadership experience and a proven track record of driving profitable growth and value creation across a range of prominent technology companies, including in the medical technology sector. We expect to benefit from his capital markets expertise, multinational company experience, financial planning and analysis skills, and strategic acumen as we build a truly global organization.”

Mr. Lo said, “I am thrilled to be joining the SSi team and supporting its mission to democratize access to advanced surgical robotic care. I believe that the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user-friendliness, training capabilities, proven track record of clinical success, and cost efficiency all distinguish SS Innovations in a large and growing global market.”

About Mr. Lo  
Gary Lo has more than three decades of financial and executive leadership experience across medical technology, healthcare, robotics, enterprise software and global technology businesses. Prior to joining the Company, Mr. Lo served as Chief Financial Officer of Subsense, Inc., a deep-technology company developing a bidirectional brain-computer interface. He previously served as Chief Financial Officer of Beyeonics Vision, a commercial-stage medical technology company developing a fully digital microscope for ophthalmic surgery; Vice President of Finance and subsequently Chief Financial Officer of Cellares Corporation, a cell therapy manufacturing robotics company; Vice President of Finance for Legrand’s Building Control Systems division, a global business with operations in North America and Asia; Vice President of Business Development (M&A) and IT at Sparta Systems; and Chief Financial Officer of 1WorldSync, a global cloud-based product data management company.

At the start of his career, Mr. Lo held progressively senior finance and technology leadership positions at Johnson & Johnson, finance leadership positions at Siebel Systems and Boston Scientific, and a senior auditor role at PricewaterhouseCoopers. Mr. Lo is a licensed Certified Public Accountant (CPA). He earned a Master of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science in Accounting, magna cum laude, from Boston College.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures, including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch-panel monitor for displaying all patient-related information, a virtual real-time image of the robotic patient-side arm carts, and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5 mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.

Forward–Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group       
Kalle Ahl, CFA             
T: (303) 953-9878       
kalle.ahl@theequitygroup.com

Devin Sullivan, Managing Director
T: (212) 836-9608
devin.sullivan@theequitygroup.com

Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com

Promotes Dr. Vishwa Srivastava to President and Appoints Gary Lo as Chief Financial Officer

FORT LAUDERDALE, Fla., Nov. 13, 2026 (GLOBE NEWSWIRE) — via IBN —  SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment of Gary Lo as Chief Financial Officer. Dr. Vishwa Srivastava previously served as the Company’s Chief Executive Officer – Asia Pacific. Both executives are based in the United States.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “At this critical juncture in SS Innovations’ growth journey, we are excited to announce the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment of Gary Lo as Chief Financial Officer. Vishwa has been instrumental in the development and growth of our Asia Pacific region, and we are confident in his ability to successfully build our US business and lead our global operations during the next phase of expansion.”

Dr. Vishwa Srivastava said, “We have established a leading position in our immense home market of India, and I look forward to working closely with the team to build the required infrastructure and operations to further increase the presence of our advanced, cost-effective SSi Mantra surgical robotic system in the United States and globally in preparation for expansion. On that note, we have been responding to all queries raised by the U.S. Food and Drug Administration during its review of our 510(k) premarket notification for the SSi Mantra and we are simultaneously continuing along the pathway toward CE marking certification in the European Union.  Additionally, we have been working at our R&D facility in India finalizing a pipeline of future disruptive healthcare technologies that we plan to roll out in the coming months.”

Dr. Sudhir Srivastava continued, “Gary brings to SS Innovations more than three decades of financial leadership experience and a proven track record of driving profitable growth and value creation across a range of prominent technology companies, including in the medical technology sector. We expect to benefit from his capital markets expertise, multinational company experience, financial planning and analysis skills, and strategic acumen as we build a truly global organization.”

Mr. Lo said, “I am thrilled to be joining the SSi team and supporting its mission to democratize access to advanced surgical robotic care. I believe that the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user-friendliness, training capabilities, proven track record of clinical success, and cost efficiency all distinguish SS Innovations in a large and growing global market.”

About Mr. Lo  
Gary Lo has more than three decades of financial and executive leadership experience across medical technology, healthcare, robotics, enterprise software and global technology businesses. Prior to joining the Company, Mr. Lo served as Chief Financial Officer of Subsense, Inc., a deep-technology company developing a bidirectional brain-computer interface. He previously served as Chief Financial Officer of Beyeonics Vision, a commercial-stage medical technology company developing a fully digital microscope for ophthalmic surgery; Vice President of Finance and subsequently Chief Financial Officer of Cellares Corporation, a cell therapy manufacturing robotics company; Vice President of Finance for Legrand’s Building Control Systems division, a global business with operations in North America and Asia; Vice President of Business Development (M&A) and IT at Sparta Systems; and Chief Financial Officer of 1WorldSync, a global cloud-based product data management company.

At the start of his career, Mr. Lo held progressively senior finance and technology leadership positions at Johnson & Johnson, finance leadership positions at Siebel Systems and Boston Scientific, and a senior auditor role at PricewaterhouseCoopers. Mr. Lo is a licensed Certified Public Accountant (CPA). He earned a Master of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science in Accounting, magna cum laude, from Boston College.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures, including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch-panel monitor for displaying all patient-related information, a virtual real-time image of the robotic patient-side arm carts, and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5 mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.

Forward–Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group       
Kalle Ahl, CFA             
T: (303) 953-9878       
kalle.ahl@theequitygroup.com

Devin Sullivan, Managing Director
T: (212) 836-9608
devin.sullivan@theequitygroup.com

Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com

Veteran global investor and former NYSE-listed asset manager CEO joins as independent director and Chair of the Audit Committee

MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) — Axe Compute (NASDAQ: AGPU), a neocloud AI infrastructure company delivering dedicated, bare-metal GPU compute and large-scale AI factory build-outs at global scale, today announced the appointment of Guang Yang to its Board of Directors as an independent director, effective November 9, 2026. Mr. Yang will also serve as Chair of the Board’s Audit Committee, and the Board has determined that he qualifies as an audit committee financial expert under SEC rules.

Mr. Yang brings more than three decades of experience in global capital markets, asset management and corporate transformation. He is Managing Partner of FTL Investments LLC, an investment firm focused on innovative companies, a role he has held since July 2020. He previously served as Executive Chairman and Chief Executive Officer of BrightSphere Investment Group Inc., a publicly traded asset manager, after serving as its Lead Independent Director. Earlier in his career, Mr. Yang spent 15 years at Franklin Templeton Investments, where he served as Executive Vice President and Senior Portfolio Manager of Global Equities.

“Guang has spent his career allocating capital across global markets and leading a public company through a period of significant change, and that is exactly the perspective we want on our Board as we scale,” said Christopher Miglino, Chairman and Chief Executive Officer of Axe Compute. “His experience in global financial markets, his deep understanding of how institutional investors evaluate growth companies, and his financial expertise make him an ideal Chair of our Audit Committee. We are fortunate to have him join us.”

“Axe Compute has built a capital-efficient model for delivering AI infrastructure at a moment when demand for GPU compute continues to outpace supply,” said Mr. Yang. “I look forward to working with Chris, the Board and the management team to support the company’s growth and to help maintain the financial discipline and governance that long-term investors expect.”

Mr. Yang holds a Ph.D. from the Australian National University, an M.B.A. from Harvard Business School and a B.S. from the University of Science and Technology of China. He has held the Chartered Financial Analyst designation since 1998.

With Mr. Yang’s appointment, the Axe Compute Board of Directors consists of five directors, a majority of whom are independent. Additional information regarding the appointment is included in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.

About Axe Compute Inc.

Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure platform built on a fundamental premise: AI innovation should not be constrained by hardware choice or availability. The company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two core offerings: Axe Compute Access, delivering a wide range of the latest high-performance GPU infrastructure across global locations, and Axe Compute Build, enabling the design, deployment, ownership, and operation of large-scale, dedicated AI factories worldwide. All solutions are supported by enterprise-grade SLAs and operational expertise. Axe Compute is headquartered in Miami, Florida. For more information, visit axecompute.com.

Media and Investor Relations Contact:

Erin McMahon

ir@axecompute.com

axecompute.com | NASDAQ: AGPU

CULVER CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced that four titles from its publishing portfolio will be featured with playable demos at an exclusive gaming showcase hosted by Noiz.gg during TwitchCon Weekend. The showcase will feature a mix of released and upcoming titles from Snail Games’ indie branch, Wandering Wizard’s publishing portfolio, including Dead Party, Whispers of West Grove, Gobby Gang, and Veil of Madness.

Dead Party is currently available on Steam, with a console release coming soon. Whispers of West Grove, Gobby Gang, and Veil of Madness are unreleased titles. The playable demos will offer attendees and creators an opportunity to get an early look at their upcoming gameplay through hands-on experiences, provide opportunities to generate organic gameplay content, and introduce new audiences to the Company’s expanding indie publishing portfolio.

The four featured titles represent a range of gameplay experiences and content opportunities:

• Dead Party: A four-player co-op action game where players defend their neighborhood against invading zombies using makeshift barricades, creative traps, powerful weapons, and rock music across multiple game modes.
• Whispers of West Grove: A psychological horror adventure set in a nightmarish psychiatric hospital, where players solve intricate puzzles and uncover the secrets behind their increasingly disturbing surroundings.
• Gobby Gang: A chaotic co-op treasure-hunting adventure where players team up to explore destructible underground caves, collect valuable loot, battle quirky creatures, and make a daring escape before their expedition goes sideways.
• Veil of Madness: A first-person psychological horror deckbuilder where players venture into the fractured consciousness of a comatose patient, exploring surreal nightmare environments and battling manifestations of her subconscious through strategic card-based combat.

For creators interested in attendance or collaborations, please reach out to creatordirect@noiz.gg

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding the four titles from the Company’s publishing portfolio being featured with playable demos at an exclusive gaming showcase hosted by Noiz.gg and the playable demos providing opportunities for creators to experience the titles firsthand, generate organic gameplay content, and introduce new audiences to the Company’s expanding publishing portfolio. Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business is included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including the risk that the exclusive gaming showcase and playable demos will be successful and the other risk factors set forth in its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail Games, and Snail Games does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
SNAL@gateway-grp.com

MONROE TOWNSHIP, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader in intelligent maritime solutions and services, today announced the pricing of its previously announced public offering of 6,000,000 shares of common stock together with common warrants to purchase up to 6,000,000 shares of common stock, on a “best-efforts” basis (the “Offering”). The warrants will have an exercise price of $0.50 per share and will expire 5 years from the date of issuance. The common stock is listed on the NYSE American under the symbol “OPTT”.

D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.

The closing of the Offering is expected to occur on or about November 16, 2026, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of $3.0 million from the Offering, before deducting placement agent fees and other related expenses.

The shares of common stock and common warrants are being offered by the Company pursuant to an effective registration statement on Form S-1/A (Registration No. 333-298786), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 12, 2026.

A definitive prospectus describing the terms of the proposed offering will be filed with the SEC. Once filed, it will be available on the SEC’s website at https://www.sec.gov. A copy of the definitive prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ocean Power Technologies

Ocean Power Technologies, Inc. (NYSE American: OPTT) provides intelligent maritime systems and services for defense and security, offshore energy, science and research, and offshore wind. Its PowerBuoy® platforms deliver clean, renewable power and real-time data communications for remote maritime and subsea applications. The company also offers the WAM-V® autonomous surface vehicle and Merrows™ software for multi-domain awareness. For more information, visit www.oceanpowertechnologies.com.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as “may,” “will,” “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends, and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. These risks include, but are not limited to, market conditions, regulatory developments, and other risks described in the Company’s filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading “Risk Factors” in the Company’s Annual Reports on Form 10-K for the year ended April 30, 2026. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information, or otherwise.

Contacts

Ocean Power Technologies

Investors: 609-730-0400 x401 or InvestorRelations@oceanpowertech.com

Media: 609-730-0400 x402 or MediaRelations@oceanpowertech.com